CRYCY yields 5.41% · JNJ yields 2.14%● Live data
📍 JNJ pulled ahead of the other in Year 7
Combined, CRYCY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CRYCY + JNJ for your $10,000?
China Railway Signal & Communication Corporation Limited, together with its subsidiaries, provides rail transportation control system solutions in China and internationally. It operates through three segments: Rail Transportation Control System, General Engineering Contracting, and Others. The company offers design, consultancy, and system integration services for rail transportation control system projects. It also produces and sells signal system products, communication information system products, infrastructure equipment and information systems, and other related products. In addition, the company offers construction, installation, testing, operation, and maintenance services for rail transportation control systems; and services relating to municipal engineering projects and other construction projects. Further, it engages in the investment management, technical exchange and trade, and bidding agency activities, as well as provision of project management activities. The company was founded in 1953 and is headquartered in Beijing, China. China Railway Signal & Communication Corporation Limited is a subsidiary of China Railway Signal & Communication (Group) Corporation Limited.
Full CRYCY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.